Study of the 5-HT2 antagonist ritanserin on sleep-walking cycle in the rat.
Ritanserin, a 5-HT2 receptor antagonist, was injected intraperitoneally to rats at light onset. It was found that 0.63 mg/kg decreased waking, increased the slow waves characteristic of the first stage of sleep, and decreased paradoxical sleep (PS) during the first four hours. Active waking was further decreased and slow wave stage increased during the following four hours. The number of synchronized and paradoxical sleep phases decreased whereas their duration increased during the first four hours. Ritanserin at 2.5 mg/kg decreased active waking and PS, whereas quite waking and slow wave stage were increased during the first four hours. Quiet waking was increased during the following four hours. It is concluded that serotonin acting on 5 HT2 receptors is actively involved in sleep-waking regulation.[1]References
- Study of the 5-HT2 antagonist ritanserin on sleep-walking cycle in the rat. Silhol, S., Glin, L., Gottesmann, C. Pharmacol. Biochem. Behav. (1992) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
